{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:25:47Z","timestamp":1760549147887},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,10,22]],"date-time":"2011-10-22T00:00:00Z","timestamp":1319241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00280-011-1761-2","type":"journal-article","created":{"date-parts":[[2011,10,21]],"date-time":"2011-10-21T04:14:50Z","timestamp":1319170490000},"page":"753-761","source":"Crossref","is-referenced-by-count":5,"title":["Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors"],"prefix":"10.1007","volume":"69","author":[{"given":"Max E.","family":"Scheulen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaku","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf A.","family":"Hilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Mende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Zergebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Strumberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,22]]},"reference":[{"key":"1761_CR1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548\u2013557","journal-title":"Anticancer Drugs"},{"key":"1761_CR2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00255750","volume":"10","author":"MI Anttila","year":"1983","unstructured":"Anttila MI, Sotaniemi EA, Kairaluoma MI et al (1983) Pharmacokinetics of Ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10:150\u2013153","journal-title":"Cancer Chemother Pharmacol"},{"key":"1761_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5- fluorouracil. Clin Pharmacokinet 16:215\u2013237","journal-title":"Clin Pharmacokinet"},{"key":"1761_CR4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3109\/07357909909032859","volume":"17","author":"L Iyer","year":"1999","unstructured":"Iyer L, Ratain MJ (1999) 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17:494\u2013506","journal-title":"Cancer Investig"},{"issue":"7","key":"1761_CR5","first-page":"748","volume":"78","author":"K Tatsumi","year":"1987","unstructured":"Tatsumi K, Fukushima M, Shirasaka T et al (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748\u2013755","journal-title":"Jpn J Cancer Res"},{"issue":"17","key":"1761_CR6","first-page":"4004","volume":"53","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17):4004\u20134009","journal-title":"Cancer Res"},{"issue":"3","key":"1761_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002800050561","volume":"39","author":"T Takechi","year":"1997","unstructured":"Takechi T, Nakano K, Uchida J et al (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3):205\u2013211","journal-title":"Cancer Chemother Pharmacol"},{"key":"1761_CR8","first-page":"371","volume":"25","author":"T Shirasaka","year":"1998","unstructured":"Shirasaka T, Shimamoto Y, Kato T et al (1998) Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil [in Japanese]. Jpn J Cancer Chemother 25:371\u2013384","journal-title":"Jpn J Cancer Chemother"},{"key":"1761_CR9","first-page":"1705","volume":"21","author":"T Kato","year":"2001","unstructured":"Kato T, Shimamoto Y, Uchida J (2001) Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5- fluorouracil. Anticancer Res 21:1705\u20131712","journal-title":"Anticancer Res"},{"key":"1761_CR10","unstructured":"The effect of food on the pharmacokinetics of S-1 after single administration in human plasma of patients with solid tumors (2001) Clinical Study Report (Taiho Pharmaceutical Co., Ltd.)"},{"key":"1761_CR11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1046\/j.1365-2036.1998.00416.x","volume":"12","author":"V Savarino","year":"1998","unstructured":"Savarino V, Mela GS, Zentilin G et al (1998) Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 12:1241\u20131247","journal-title":"Aliment Pharmacol Ther"},{"key":"1761_CR12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1365-2036.2002.01232.x","volume":"16","author":"R Tutuian","year":"2002","unstructured":"Tutuian R, Katz PO, Bochenek W et al (2002) Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40\u00a0mg, in healthy volunteers. Aliment Pharmacol Ther 16:829\u2013836","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"1761_CR13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, ACTS-GC Group et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810\u20131820","journal-title":"N Engl J Med"},{"issue":"3","key":"1761_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221","journal-title":"Lancet Oncol"},{"issue":"2","key":"1761_CR15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S1359-6349(09)71107-3","volume":"7","author":"K Kato","year":"2009","unstructured":"Kato K, Muro K, Yasui H et al (2009) The FIRIS study; a phase III trial of 5FU\/l-leucovorin\/irinotecan (FOLFIRI) versus irinotecan\/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group]. Eur J Cancer Suppl 7(2):324","journal-title":"Eur J Cancer Suppl"},{"issue":"9","key":"1761_CR16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547\u20131553","journal-title":"J Clin Oncol"},{"key":"1761_CR17","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/JCO.2009.25.9937","volume":"28","author":"H Yoshioka","year":"2010","unstructured":"Yoshioka H, Okamoto I, Morita S et al (2010) Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). J Clin Oncol 28:7s suppl; abstr 7530","journal-title":"J Clin Oncol"},{"issue":"8","key":"1761_CR18","first-page":"2000","volume":"5","author":"K Hirata","year":"1999","unstructured":"Hirata K, Horikoshi N, Aiba K et al (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8):2000\u20132005","journal-title":"Clin Cancer Res"},{"key":"1761_CR19","doi-asserted-by":"crossref","unstructured":"Yoshida K, Ikeda K, Yoshisue K et al. (2011) Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors. J Clin Oncol 29, (suppl 4; abstr 53)","DOI":"10.1200\/jco.2011.29.4_suppl.53"},{"issue":"10","key":"1761_CR20","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1158\/1078-0432.CCR-1076-03","volume":"15","author":"GJ Peters","year":"2004","unstructured":"Peters GJ, Noordhuis P, Van Groeningen CJ et al (2004) The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 15(10):4072\u20134076","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1761_CR21","first-page":"941","volume":"4","author":"B Reigner","year":"1998","unstructured":"Reigner B, Verweij J, Dirix L et al (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941\u2013948","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1761-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1761-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1761-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T05:10:08Z","timestamp":1560834608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1761-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1761-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,22]]}}}